Anzeige
Mehr »
Dienstag, 26.05.2026 - Börsentäglich über 12.000 News
Hebt diese Aktie bald ab? Größtes Wolfram-Portfolio der USA vor der Neubewertung!?
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: A3CWA4 | ISIN: GB00BMCLYF79 | Ticker-Symbol: 88Q
Xetra
26.05.26 | 17:35
5,250 Euro
-2,78 % -0,150
Branche
Biotechnologie
Aktienmarkt
Sonstige
1-Jahres-Chart
4BASEBIO PLC Chart 1 Jahr
5-Tage-Chart
4BASEBIO PLC 5-Tage-Chart
RealtimeGeldBriefZeit
5,5005,75020:46
Xetra-Umsätze heute
UhrzeitAktienkursStück
5,25034
Tagesumsatz Xetra-0,150
-2,78 %

34

 Angaben in grüner Schrift zeigen, dass der Aktienkurs im Vergleich zum vorherigen Kurs gestiegen ist. Angaben in roter Schrift zeigen gefallene Börsenkurse.

Aktuelle News zur Aktie 4BASEBIO PLC

Aktienalarm. Jetzt kostenlos anmelden!

E-Mail
Aktivieren
  • Alle
  • Pressemitteilungen
  • Empfehlungen
  • Chartanalysen
  • Berichte
ZeitAktuelle Nachrichten
Sprache: Alle DE EN
LeserMedien
Fr4basebio Plc - Director Dealing2994basebio Plc - Director Dealing PR Newswire LONDON, United Kingdom, May 22 4basebio PLC("4basebio" or the "Company") ...
► Artikel lesen
4BASEBIO Aktie jetzt für 0€ handeln
MiEARNINGS AND TRADING: 4basebio revenue surges in "step-change" year9
Mi4basebio signs clinical supply deal for Phase II trial9
Mi4basebio reports 81% revenue growth, narrows losses for 20258
Mi4basebio steigert Umsatz um 81 % - Investitionen führen zu höherem Verlust12
Weiter >>
45 Nachrichten in den letzten 12 Monaten
Das könnte Sie auch interessieren
ZeitAktuelle NachrichtenMedien
13:06Cartesian Therapeutics, Inc.: Cartesian Therapeutics Secures up to $150 Million of Non-Dilutive Financing from K2 HealthVentures and Expects Topline Data from the Phase 3 AURORA Trial in First Quarter 2027Secured up to $150 million of non-dilutive financing from K2 HealthVentures; funding of $50 million from initial tranche extends cash runway into 2028 Financing strengthens Cartesian's financial flexibility...
► Artikel lesen
17:06Alaunos Therapeutics, Inc.: Alaunos Reports Broad Metabolic Improvements with ALN1003 in Obese Mouse StudiesALN1003 demonstrated consistent, favorable effects across key drivers of metabolic disease, including reductions in body weight and fat mass, improved insulin sensitivity, enhanced adipose function...
► Artikel lesen
19:06MaaT Pharma Provides Business Update and Reports Financial Results for the First Quarter 2026 MaaT013 (Xervyteg): In May 2026, the Company was informed of a "negative trend" opinion on its Marketing Authorization Application from the Committee for Medicinal Products for Human Use...
► Artikel lesen
13:38Glow Lifetech Corp.: Glow Lifetech Reports Record Q1 2026 Results; 35% YoY Revenue Growth, 27% Sequential Growth and Continued National Expansion MomentumToronto, Ontario--(Newsfile Corp. - May 26, 2026) - Glow Lifetech Corp. (CSE: GLOW) (OTCID: GLWLF) (FSE: 9DO) ("Glow" or the "Company") is pleased to report its financial results for the first quarter...
► Artikel lesen
16:54Swedish Orphan Biovitrum AB: New analysis shows Tryngolza (olezarsen) reduced acute pancreatitis by 85% and triglycerides by 66% in severe hypertriglyceridemiaSTOCKHOLM, May 26, 2026 /PRNewswire/ -- Sobi (STO: SOBI) today announced results from a new analysis of the pivotal Phase 3 CORE and CORE2 trials, showing Tryngolza (olezarsen) reduced the...
► Artikel lesen